Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
40 participants
INTERVENTIONAL
2014-10-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Voriconazole For Chronic Bronchopulmonary Aspergillosis
NCT00159822
An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
NCT04004078
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
NCT00620074
Efficacy of Intrabronchial Voriconazole Instillation for Inoperable Pulmonary Aspergilloma
NCT03799809
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
NCT02100761
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active treatment
Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
Voriconazole
2-week long intravenous instillation of voriconazole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Voriconazole
2-week long intravenous instillation of voriconazole
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known allergy to voriconazole
* Severe impairment of live or kidney function
* Septic shock
* Unwilling to sign informed consent
30 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sir Run Run Shaw Hospital
OTHER
Zhejiang Provincial People's Hospital
OTHER
First People's Hospital of Hangzhou
OTHER
Second People's Hospital of Hangzhou
UNKNOWN
The Third Affiliated hospital of Zhejiang Chinese Medical University
OTHER
Ningbo People's Hospital
UNKNOWN
Xiaoshan People's Hospital
OTHER
Xiaoshan Hospital
UNKNOWN
The First People's Hospital of Huzhou
OTHER
Red Cross Hospital, Hangzhou, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
caichuang
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chuang Cai, doctor
Role: PRINCIPAL_INVESTIGATOR
Red Cross Hospital, Hangzhou, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hangzhou Red Cross Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Tutar N, Metan G, Koc AN, Yilmaz I, Bozkurt I, Simsek ZO, Buyukoglan H, Kanbay A, Oymak FS, Gulmez I, Demir R. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013 Sep 4;8(1):59. doi: 10.1186/2049-6958-8-59. eCollection 2013.
Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo M. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. J Med Econ. 2011;14(2):227-37. doi: 10.3111/13696998.2011.564246. Epub 2011 Mar 9.
Ader F, Bienvenu AL, Rammaert B, Nseir S. Management of invasive aspergillosis in patients with COPD: rational use of voriconazole. Int J Chron Obstruct Pulmon Dis. 2009;4:279-87. doi: 10.2147/copd.s4229. Epub 2009 Aug 3.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hangzhou Red Cross Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.